This company listing is no longer active
2197 Stock Overview
A biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Clover Biopharmaceuticals, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.97 |
| 52 Week High | HK$2.18 |
| 52 Week Low | HK$0.91 |
| Beta | 0 |
| 11 Month Change | 1.04% |
| 3 Month Change | -8.49% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2197 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -17.8% | 0.4% | -1.4% |
| 1Y | n/a | -31.1% | 1.3% |
Return vs Industry: Insufficient data to determine how 2197 performed against the Hong Kong Biotechs industry.
Return vs Market: Insufficient data to determine how 2197 performed against the Hong Kong Market.
Price Volatility
| 2197 volatility | |
|---|---|
| 2197 Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2197's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2197's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 681 | Joshua G. Liang | www.cloverbiopharma.com |
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of vaccines and biologic therapeutic candidates. The company develops SCB-2019 (CpG 1018/Alum), an adjuvanted protein-based COVID-19 vaccine candidate; AdimFlu-S (QIS), a quadrivalent vaccine for the treatment of influenza; SCB-2020S (CAS-1) and Multivalent SARS-CoV-2, a COVID-19 vaccine candidate; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-219M, a human thrombopoietin receptor agonist (TPO-RA), which is in Phase 1 trial for the treatment of chemotherapy-induced thrombocytopenia; and SCB-1001, a rabies vaccine candidate. It develops its vaccines through Trimer-Tag technology platform.
Clover Biopharmaceuticals, Ltd. Fundamentals Summary
| 2197 fundamental statistics | |
|---|---|
| Market cap | HK$1.26b |
| Earnings (TTM) | -HK$713.12m |
| Revenue (TTM) | HK$275.52k |
4,556x
P/S Ratio-1.8x
P/E RatioIs 2197 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2197 income statement (TTM) | |
|---|---|
| Revenue | CN¥257.00k |
| Cost of Revenue | CN¥1.72b |
| Gross Profit | -CN¥1.72b |
| Other Expenses | -CN¥1.05b |
| Earnings | -CN¥665.19m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.51 |
| Gross Margin | -669,157.20% |
| Net Profit Margin | -258,830.35% |
| Debt/Equity Ratio | 1,435.8% |
How did 2197 perform over the long term?
See historical performance and comparison